p.79 抽出テキスト
CLINICAL STATEMENTS AND GUIDELINES Circulation. 2023;148:e9–e119. DOI: 10.1161/CIR.0000000000001168 August 29, 2023 Virani et al 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline 37 Bom MJ, van Diemen PA, Driessen RS, et al. Prognostic value of [15O] H2O positron emission tomography-derived global and regional myocardial perfusion. Eur Heart J Cardiovasc Imaging. 2020;21:777–786. 38. Kay J, Dorbala S, Goyal A, et al. Influence of sex on risk stratification with stress myocardial perfusion Rb-82 positron emission tomography: results from the PET (positron emission tomography) prognosis multicenter registry. J Am Coll Cardiol. 2013;62:1866–1876. 39. Schenker MP, Dorbala S, Hong EC, et al. Interrelation of coronary calcification, myocardial ischemia, and outcomes in patients with intermediate likelihood of coronary artery disease: a combined positron emission tomography/computed tomography study. Circulation. 2008;117:1693–1700. 40. Motoyama S, Ito H, Sarai M, et al. Plaque characterization by coronary computed tomography angiography and the likelihood of acute coronary events in mid-term follow-up. J Am Coll Cardiol. 2015;66:337–346. 41. Ferencik M, Mayrhofer T, Bittner DO, et al. Use of high-risk coronary atherosclerotic plaque detection for risk stratification of patients with stable chest pain: a secondary analysis of the PROMISE randomized clinical trial. JAMA Cardiol. 2018;3:144–152. 42. Williams MC, Kwiecinski J, Doris M, et al. Low-attenuation noncalcified plaque on coronary computed tomography angiography predicts myocardial infarction: results from the multicenter SCOT-HEART trial (Scottish Computed Tomography of the HEART). Circulation. 2020;141:1452–1462. 43. Bingham SE, Hachamovitch R. Incremental prognostic significance of combined cardiac magnetic resonance imaging, adenosine stress perfusion, delayed enhancement, and left ventricular function over preimaging information for the prediction of adverse events. Circulation. 2011;123:1509– 1518. 44. Indorkar R, Kwong RY, Romano S, et al. Global coronary flow reserve measured during stress cardiac magnetic resonance imaging is an independent predictor of adverse cardiovascular events. J Am Coll Cardiol Img. 2019;12:1686–1695. 45. Douglas PS, Hoffmann U, Patel MR, et al. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med. 2015;372:1291–1300. 46. Hoffmann U, Ferencik M, Udelson JE, et al. Prognostic value of noninvasive cardiovascular testing in patients with stable chest pain: insights from the PROMISE trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). Circulation. 2017;135:2320–2332. 47. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2022;145:e18–e114. 48. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/ SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130:1749–1767. 49. Califf RM, Armstrong PW, Carver JR, et al. Task force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol. 1996;27:1007–1019. 50. Mark DB, Shaw L, Harrell FE Jr., et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med. 1991;325:849–853. 51. Perera D, Clayton T, O'Kane PD, et al. Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med. 2022;387:1351–1360. 52. Andreini D, Pontone G, Pepi M, et al. Diagnostic accuracy of multidetector computed tomography coronary angiography in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2007;49:2044–2050. 4.1. General Approach to Treatment Decisions 1. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–1516. 2. Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359:677–687. 3. Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382:1395–1407. 4. Bangalore S, Steg G, Deedwania P, et al. Beta-blocker use and clinical out- comes in stable outpatients with and without coronary artery disease. JAMA. 2012;308:1340–1349. 5 Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nife- dipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004;364:849–857. 6. Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009;53:1510–1516. 7. Ferrari R, Pavasini R, Camici PG, et al. Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment. Eur Heart J. 2019;40:190–194. 8. Arnold SV, Jang JS, Tang F, et al. Prediction of residual angina after percutaneous coronary intervention. Eur Heart J Qual Care Clin Outcomes. 2015;1:23–30. 9. Zhang Z, Jones P, Weintraub WS, et al. Predicting the benefits of percutaneous coronary intervention on 1-year angina and quality of life in stable ischemic heart disease: risk models from the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). Circ Cardiovasc Qual Outcomes. 2018;11:e003971. 10. Longmore RB, Spertus JA, Alexander KP, et al. Angina frequency after myocardial infarction and quality of life in older versus younger adults: the Prospective Registry Evaluating Myocardial Infarction: Event and Recovery study. Am Heart J. 2011;161:631–638. 11. Ruo B, Rumsfeld JS, Hlatky MA, et al. Depressive symptoms and healthrelated quality of life: the Heart and Soul Study. JAMA. 2003;290:215–221. 12. Spertus JA, Jones PG, Maron DJ, et al. Health-status outcomes with invasive or conservative care in coronary disease. N Engl J Med. 2020;382:1408– 1419. 13. McAlister FA, Majumdar SR, Lin M, et al. Cholesterol end points predict outcome in patients with coronary disease: quality improvement metrics from the enhancing secondary prevention in coronary artery disease (ESP-CAD) trial. Can J Cardiol. 2014;30:1627–1632. 14. Waldeyer C, Seiffert M, Staebe N, et al. Lipid management after first diagnosis of coronary artery disease: contemporary results from an observational cohort study. Clin Ther. 2017;39:2311–2320.e2. 15. Rana JS, Virani SS, Moffet HH, et al. Association of low-density lipoprotein testing after an atherosclerotic cardiovascular event with subsequent statin adherence and intensification. Am J Med. 2022;135:603–606. 16. Garcia BH, Giverhaug T, Hoegli JU, et al. A pharmacist-led follow-up program for patients with established coronary heart disease in North Norway: a randomized controlled trial. Pharm Pract (Granada). 2015;13:575. 17. Gyberg V, De Bacquer D, De Backer G, et al. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovasc Diabetol. 2015;14:133. 18. Pocock S, Brieger DB, Owen R, et al. Health-related quality of life 1-3 years post-myocardial infarction: its impact on prognosis. Open Heart. 2021;8:e001499. 19. Shafiq A, Arnold SV, Gosch K, et al. Patient and physician discordance in reporting symptoms of angina among stable coronary artery disease patients: insights from the Angina Prevalence and Provider Evaluation of Angina Relief (APPEAR) study. Am Heart J. 2016;175:94–100. 20. Beltrame JF, Weekes AJ, Morgan C, et al. The prevalence of weekly angina among patients with chronic stable angina in primary care practices. Arch Intern Med. 2009;169:1491–1499. 21. Saxon JT, Chan PS, Tran AT, et al. Comparison of patient-reported vs physician-estimated angina in patients undergoing elective and urgent percutaneous coronary intervention. JAMA Netw Open. 2020;3:e207406. 22. Qintar M, Spertus JA, Gosch KL, et al. Effect of angina under-recognition on treatment in outpatients with stable ischaemic heart disease. Eur Heart J Qual Care Clin Outcomes. 2016;2:208–214. 23. Arnold SV, Grodzinsky A, Gosch KL, et al. Predictors of physician underrecognition of angina in outpatients with stable coronary artery disease. Circ Cardiovasc Qual Outcomes. 2016;9:554–559. 24. Bayati T, Dehghan A, Bonyadi F, et al. Investigating the effect of education on health literacy and its relation to health-promoting behaviors in health center. J Educ Health Promot. 2018;7:127. 25. van der Heide I, Wang J, Droomers M, et al. The relationship between health, education, and health literacy: results from the Dutch Adult Literacy and Life Skills Survey. J Health Commun. 2013;18(suppl 1):172–184. 26. Thompson D, Al-Lamee R, Foley M, et al. Achieving optimal adherence to medical therapy by telehealth: findings from the ORBITA medication adherence sub-study. Pharmacol Res Perspect. 2021;9:e00710. Downloaded from http://ahajournals.org by on October 7, 2026